CClinicalTrials.gg
RecruitingNCT06045702CFTR-EPUpdated Mar 20, 2026

Establishment of a Primary Epididymal Cell Model From Epididymal Samples to Study CFTR Gene Regulation

An observational study in Cystic Fibrosis, Congenital Bilateral Absence of Vas Deferens and Sterility, Male, sponsored by University Hospital, Brest. Recruiting at 1 site in France. Open to male participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-20.

Sponsored by University Hospital, Brest · Observational

From the registry’s dates

  • Started Sep 2024; still recruiting 2 years later.
Study type
Observational
Model
Other
Time perspective
Prospective
Enrollment
20
Ages
18 Years and older
Sex
Male
01

Study summary

The aim of this observational study is to better understand the role and involvement of the regulatory elements of the CFTR gene, with the aim of better describing the 3D organisation of chromatin at the CFTR locus in epididymal cells in patients with male infertility of any kind, or with cystic fibrosis or bilateral agenesis of the vas deferens, requiring scheduled surgery.

The main questions it aims to answer are:

  • to better characterise this 3D organisation of the CFTR locus, the study of regulatory elements in primary epididymal cells is the most relevant and realistic model.
  • to gain a better understanding of the regulation of the CFTR gene in epididymal cells in order to gain a better understanding of the pathology of male infertility caused by bilateral agenesis of the vas deferens, a symptom and also a borderline form of cystic fibrosis.

Participants will Epididymal samples will be taken by a urologist for the AMP department during the planned surgery. The rest of the samples taken will be recovered for research purposes, with the aim of recovering the epididymal cells contained in the sample. This is in no way an additional procedure and will have no impact on the patient's health..

02

Conditions studied

  • Cystic Fibrosis
  • Congenital Bilateral Absence of Vas Deferens
  • Sterility, Male

Keywords

  • Infertility
  • Primary epididymal cells
03

In context

Cystic Fibrosis

1,581 studies on the registry are indexed under Cystic Fibrosis; 190 are open to participants now.

This study's planned enrollment of 20 is below the median of 85 across 482 observational studies indexed under Cystic Fibrosis.

Browse Cystic Fibrosis studies →

Lead sponsor

University Hospital, Brest is the lead sponsor of 594 studies on the registry; 135 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The target population for this study will be adult male patients with all types of male infertility due to genital defects, including epididymal defects due to obstruction or agenesis of the vas deferens, cystic fibrosis or male infertility due to bilateral agenesis of the vas deferens.

Inclusion criteria

  • Male patients over 18 years of age
  • Patients, without genetic pathology, scheduled for epididymal sampling surgery
  • Patients with cystic fibrosis or bilateral vas deferens agenesis, scheduled for epididymal sampling surgery.
  • Signature of a consent form

Exclusion criteria

Exclusion Criteria:

  • Patients not scheduled for epididymal harvesting surgery
  • Patients under legal protection (guardianship, curatorship)
  • Refusal to participate
05

Study design

Observational model
Other
Time perspective
Prospective
Enrollment
20 participants (estimated)
Patient registry
No

Groups and cohorts

  • Group control

    Adult patients with no genetic pathology other than male infertility of any type leading to an inability to procreate without medical assistance, and requiring surgery to recover spermatozoa for possible in vitro fertilization.

    Procedure: Epididymal sample

  • CFTR-associated pathology

    Major patients with cystic fibrosis or male infertility due to agenesis of the vas deferens. These patients will be included in the study because they have the prospect of procreation by in vitro fertilisation requiring surgery to recover spermatozoa.

    Procedure: Epididymal sample

Interventions

  • ProcedureEpididymal sample

    During a planned surgical procedure carried out by the Urology and Medically Assisted Reproduction (MAP) department at Brest University Hospital in the patients included in the study, a remnant epididymal sample (between ½ and ¼ of a cc) will be kept for research purposes. These patients suffer from male infertility, leading them to undergo surgery in order to check for the presence of spermatozoa in the epididymis, and to recover spermatozoa which will be frozen and flaked in the AMP department of the CHU Brest, in the event of future procreation by in vitro fertilisation.

06

What researchers measure

Primary outcomes

  1. 3D organisation of chromatin at the CFTR locus

    Cultur Cell Model

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — All collected data that underlie results in a publication

Supporting information: Study protocol

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Mar 20, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06045702
Lead sponsor
University Hospital, Brest
Responsible party
Sponsor
First posted
Sep 21, 2023
Start date
Sep 11, 2024
Primary completion
Sep 9, 2026 (estimated)
Completion
Sep 11, 2026 (estimated)
Last update
Mar 20, 2026

Study contacts

Antoine VALERI, MD,PhD
Contact
Antoine.Valeri@univ-brest.fr
+33298347170
Stéphanie MOISAN, PhD
Contact
stephanie.moisan@chu-brest.fr
+332 98 01 65 67
Antoine VALERI, MD,PhD
principal investigator · University Hospital, Brest

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion